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Primary hyperparathyroidism (PHPT) may be associated with arterial hypertension. The underlying mechanisms are not fully
understood and reversibility by parathyroid surgery is controversial. This study aimed to characterize pressor hormones, vascular
reactivity to norepinephrine, and cytosolic-free calcium in platelets in 15 hypertensive patients with hypercalcaemic PHPT
before and after successful parathyroidectomy and to compare them with 5 pre-hypertensive patients with normocalcaemic
PHPT, 8 normotensive patients with hypercalcaemic PHPT and 15 normal controls. Hypertensive patients with hypercalcaemic
PHPT had slightly higher levels of pressor hormones (P<0.05), enhanced cardiovascular reactivity to norepinephrine (P<
0.05) and increased cytosolic calcium in platelets (P<0.05) than controls. Pre-hypertensive patients with normocalcaemic
PHPT had intermediate values of increased cardiovascular reactivity and cytosolic calcium. Normotensive patients with
hypercalcaemic PHPT and normotensive controls had comparable pressor hormone concentrations and intracellular calcium
levels. Successful parathyroidectomy was associated with normal blood pressure values and normalisation of pressor hormone
concentrations, cardiovascular pressor reactivity and cytosolic free calcium. Our results suggest that parathyroid hypertension
is mediated/maintained, at least in part, by functional alterations of vascular smooth muscle cells and can be cured by
parathyroidectomy in those patients who do not have primary hypertension.
1.Introduction
Sporadic primary hyperparathyroidism (PHPT) is an endo-
crine disorder usually characterized by persistent fasting
hypercalcaemia attributable to autonomous overproduction
of parathyroid hormone (PTH) by parathyroid adenoma or
hyperplasia (hypercalcaemic PHPT). However, a proportion
of patients with PHPT (20%) show normal total and
ionized serum calcium levels in the presence of persistently
elevated PTH concentrations [1–3]. Initially, there have been
questions about the existence of this new clinical phenotype
of PHPT, as well as about the correctness of the term
“normocalcaemic PHPT”. However, at the 2002 consensus
conference, normocalcaemic PHPT was appreciated as a
distinct entity of PHPT. Whether or not normocalcaemic
PHPT represents an earlier form or a forme fruste of the
disease is subject to discussion [4].
PHPT is associated with increased risk of arterial hyper-
tension. Recent investigations have reported high blood
pressure in 40 to 65% of patients with PHPT [5–9]. Despite
variations in published data due to diﬀerent patient selection
criteria, the prevalence of hypertension in patients with
PHPT is higher than in the general population regardless
of age [5, 10]. However, elevated PTH levels have also been
reported in a subgroup of patients with primary (essential)
hypertension [11]. Thus, in daily practice the association
of high concentrations of PTH with high blood pressure
may not necessarily have a causal relationship as PHPT
and primary hypertension are frequent and may coincide in
patients older than 50 years. Consistent with the assumption
of coincidence of both diseases is the observation that more
than 50% of PHPT patients remain hypertensive in spite of
successful parathyroidectomy.2 International Journal of Endocrinology
At present the mechanisms underlying parathyroid
hypertension are not clear. Systemic hypertension accom-
panying hypercalcaemic PHPT is haemodynamically char-
acterized by increased total peripheral vascular resistance
[12, 13]. Proposed factors producing hypertension in PHPT
include (a) abnormalities in major endocrine pressor factors,
such as the sympathetic nervous system and/or the renin-
angiotensin-aldosterone axis [14, 15]a n d( b )d y s f u n c t i o no r
structural changes of resistance vessels documented either by
analteredvasodilatoryresponse[16,17]and/oranenhanced
vascular constriction to pressor hormones [18–20].
Regardless of the precise nature of the operating factors,
abnormal calcium metabolism at the level of the vascular
smooth muscle cells may be the ﬁnal common pathway
for functional alterations of vascular tone and vascular
reactivity and ﬁnally for increased total peripheral vascular
resistance.
The aim of this study was to evaluate circulating levels
of vasopressor hormones, cytosolic calcium in platelets
and cardiovascular pressor response to norepinephrine in
patients with diﬀerent forms of PHPT and to characterize
the changes in blood pressure and in proposed causes of
bloodpressuredysregulationinpatientswithhypercalcaemic
PHPT and hypertension before and after parathyroid-
ectomy.
2. Patientsand Methods
2.1. Study Population. Three groups of patients and
one group of healthy subjects were included in the
study. Group 1 were ﬁfteen patients with hypercalcaemic
PHPT and untreated chronic arterial hypertension (RR ≥
140/90mmHg). Group 2 included 8 patients with hyper-
calcaemic PHPT and normotension (blood pressure less
than 120/80mmHg). Group 3 included 5 patients with
normocalcaemic PHPT and untreated prehypertension (RR
120–139mmHg/80–89mmHg), and Group 4 consisted of
15 healthy normotensive subjects (age-, sex-, and body
weight-matched to patients from Group 1). Patients with
PHPT were accepted only if they had no family history
of primary hypertension or known long-standing personal
history of primary hypertension. The known duration of
arterial hypertension was short in all patients (less than
6 months). Antihypertensive drugs were discontinued at
least 4 weeks before the study. None of the participants of
the investigation had taken any medication interfering with
plateletfunctionorproductionforatleast3weeks.Informed
written consent was obtained from all study participants,
and the study protocol was approved by the local ethics
committee [21].
2.1.1. Characteristics of the Study Groups (Table 1). The three
patientgroupsandthenormalsubjectsdidnotdiﬀerinmean
age, in the predominance of female participants, and had
similar renal function. The two patient groups (Group 1 and
2) with hypercalcaemic PHPT did not diﬀer in mean serum
total calcium concentrations, mean serum phosphate con-
centrations, and mean iPTH levels. Compared to these two
hypercalcaemic PHPT patient groups, the normocalcaemic
patients from Group 3 had signiﬁcantly lower PTH levels.
The prevalence of left ventricular hypertrophy (LVH) was
high in all patients aﬀe c t e db yP H P T( 1 0o u to f1 5p a t i e n t s
from Group 1, 5 out of 8 patients from Group 2 and 3 out of
5 patients from Group 3). Neither the prevalence of LVH nor
its severity showed a correlation with high blood pressure.
2.1.2. Deﬁnitions and Classiﬁcations
( a )S p o r a d i cP H P T .Hypercalcaemic PHPT was deﬁned by
persistent supranormal total serum calcium levels (more
than 2.6mmol/L) and supranormal ionized calcium (more
than 1.35mmol/L) together with supranormal serum intact
PTH (iPTH) level (more than 55ng/L). Normocalcaemic
PHPT was deﬁned by the repeated demonstrations of
consistently normal serum total and ionized calcium levels
with persistently abnormal serum iPTH. The diagnosis of
normocalcaemic PHPT was made when vitamin-D deﬁ-
ciencybymeasurementsof25-hydroxyvitaminD3(lessthan
20ng/mL) was excluded. None of these patients had any
familyhistoryofhypercalcaemia;theyallhadnormalorhigh
urinary calcium excretion to an extent excluding familial
hypocalcuric hypercalcaemia. None of the patients with
normo- or hypercalcaemic PHPT had reduced glomerular
ﬁltration (estimated by creatinine clearance) or was taking
thiazides, lithium or other drugs known to aﬀect calcium
metabolism.
(b) Chronic Arterial Hypertension. Chronic arterial hyper-
tension was deﬁned by constant blood pressure values above
140/90mmHg documented on repeated readings at clinical
visits or at home. Normotension was deﬁned as blood
pressure values below 120/80mmHg. The Joint National
Committee on Prevention, Detection, Evaluation, and Treat-
ment of high blood pressure, deﬁned prehypertension as a
predisease state with systolic blood pressures ranging from
120 to 139mmHg and diastolic blood pressures from 80
to 89mmHg [22]. The classiﬁcation of blood pressure as
normal, pre-hypertensive or hypertensive was conﬁrmed by
24-hour ambulatory blood pressure monitoring.
In contrast to primary (essential) hypertension, sec-
ondary hypertension was deﬁned as high blood pressure
which is caused by an identiﬁable underlying cause (renal,
haematologic, or cardiovascular diseases, endocrine disor-
ders, or drug use). Secondary forms of high blood pressure
other than parathyroid hypertension were excluded by clin-
ical examination and established tests including estimation
of renal function, urinalysis, renal ultrasound, Duplex and
Doppler ultrasound, determinations of haematocrit, serum
electrolytes and fasting blood glucose, hormonal analysis of
thyroid, and if appropriate of adrenal function and chest
radiograph.
(c) Left Ventricular Hypertrophy. Echocardiography was per-
formed using two-dimensional guided M-mode echocardio-
graphy according to the recommendations of the American
Society of Echocardiography [23]. Left ventricular mass
was estimated with the anatomically validated formula byInternational Journal of Endocrinology 3
Table 1: Characteristics of patients with PHPT (Group 1–3) and age-and sex matched normal subjects (Group 4).
Group 1 Group 2 Group 3 Group 4
N 15 8 5 15
age, years 58 ± 96 1 ± 56 0 ± 85 8 ± 12
Gender(F/m) 9/6 5/3 4/1 9/6
GFR, mL/min/1.73m2 115 ± 9 120 ± 8 111 ± 8 121 ± 12
Serum calcium mMol/L 3.2 ± 0.2∗ 3.1 ± 0.1∗ 2.5 ± 0.1∗ 2.3 ± 0.1
Serum phosphate, mMol/L 0.8 ± 0.1∗ 0.8 ± 0.2∗ 1.0 ± 0.2∗ 1.4 ± 0.2
Serum PTH, pg/mL 212 ± 31∗ 292 ± 28∗ 97 ± 13∗ 32 ± 6
∗P<0.05 versus healthy subjects.
Group 1 hypercalcaemic, hypertensive patients with PHPT.
Group 2 hypercalcaemic, normotensive patients with PHPT.
Group 2 normocalcaemic, pre-hypertensive patients with PHPT.
Group 2 normal subjects.
Devereux et al. [24] and deﬁned as LV mass index 49.2g/m2
in men and 46.7g/m2 in women.
2.2. Study Protocol. Blood pressure recordings were per-
formed using a standard cuﬀ and sphygmomanometer, and
blood samples were taken through an intravenous cannula
for the determination of serum total calcium and inorganic
phosphate (by autoanalyzer techniques), iPTH (by a two
site immunoreactive assay for 1–84 human parathyroid
hormone monoclonal antibodies), plasma renin activityand
plasma aldosterone (by radioimmunoassay), and plasma
norepinephrine (by radioenzymatic method). Intracellular
free calcium concentrations in platelets were measured by
Quin-2AM [25].
The cardiovascular pressor reactivity to intravenously
infused norepinephrine (1-norepinephrine tartrate in 5%
glucose) was determined while the participants were in the
supine position as described previously [21] .T h er a t eo f
infused norepinephrine was increased stepwise until the
blood pressure stabilized for at least 10 minutes at diﬀerent
levels. Two targets, namely, 10 to 15mmHg and 25 to
30mmHgabovethebasalmeanarterialbloodpressure,were
chosen. The pressor dose of norepinephrine was deﬁned as
the dose necessary to increase the mean blood pressure by
20mmHg.
The cardiovascular pressor response to norepinephrine
was studied in hypercalcaemic PHPT patients with hyper-
tension prior to surgery and 3 months after surgical cor-
rection of PHPT. Normocalcaemic Patients with PHPT and
normotensive controls were studied once.
Study Group 1 was tested twice, that is, prior to surgery
and after 3 months after surgery; Groups 3 and 4 were
studied once, and Group 2 was not available for study.
Hypercalcaemic PHPT with normotension were not
available for this part of the investigations.
2.3. Data Analysis. Results are given as means ± SD. Natural
logarithmic transformation of plasma renin activity, plasma
aldosterone, plasma norepinephrine and pressor dose was
done, and comparisons between groups were performed
using the Mann-Whitney U test. The Student paired test
was used for comparison of the pre- and postoperative
values in the hypertensive hypercalcaemic PHPT patients.
Correlations were calculated by the Spearman rank method.
P values less than 0.05 were regarded as signiﬁcant. All
statistical calculations were done with the SPSS version 10
(SPSS Inc., Chicago, Il, USA).
3. Results
Blood pressure, pressor hormones, cardiovascular nore-
pinephrinereactivity,andcytosoliccalciuminplateletsinthe
study groups are given in Table 2.
Systolic, diastolic, and mean blood pressure levels in
hypercalcaemic PHPT patients with hypertension (Group 1)
were signiﬁcantly higher than in hypercalcaemic PHPT
patients with normotension (Group 2) or in healthy subjects
(Group 4). Prehypertensive patients with normocalcaemic
PHPT (Group 3) had intermediate values.
Patients from Group 1 had signiﬁcantly higher mean
plasma renin activity, plasma aldosterone, and nore-
pinephrine levels than matched healthy subjects from Group
4. There were no signiﬁcant diﬀerences between healthy
subjects and patients from Group 2 and 3. None of these
pressor hormones correlated positively either with blood
pressure or PTH levels.
The pressor doses of norepinephrine were tested in
Group 1, 3, and 4. They were signiﬁcantly lower in Group
1 (hypertensive patients with hypercalcaemic PHPT) and
in Group 3 (prehypertensive patients with normocalcaemic
PHPT) by comparison with healthy subjects from Group 4.
There were signiﬁcant diﬀerences in mean platelet
calcium concentrations between Group 1 and Group 3,
respectively, compared to patients from Group 2 and
Group 4. A close correlation between platelet cytosolic
calcium levels and mean blood pressure was apparent when
all 43 participants were included (r = 0.9, P<. 01).
Preoperative values of all patients from Group 1 are
given in Tables 1 and 2. Removal of a parathyroid adenoma
(13 cases) or subtotal (3.5) parathyroidectomy (2 cases
of parathyroid hyperplasia) was successful in all hyper-
tensive patients with hypercalcaemic PHPT. Circulating
parathormone concentrations (32 ± 5pg/mL) and serum
calcium levels (2.3 ± 0.1mmol/L) were normalized in4 International Journal of Endocrinology
Table 2: Blood pressure, pressor hormones, cytosolic calcium and cardiovascular reactivity to norepinephrine in PHPT patients and age and
sex matched normotensive subjects.
Group 1 Group 2 Group 3 Group 4
Blood pressure, mmHg 171/111 ± 10/8∗ 118/70 ± 4/3 135/85 ± 3/2 120/70 ± 4/3
Plasma Renin activity ng/mL/h 1.6 ± 0.2∗ 1.5 ± 0.1 1.3 ± 0.3 1.4 ± 0.2
Plasma aldosterone ng/100mL 5.2 ± 1.1∗ 4.5 ± 0.9 4.7 ± 0.9 4.2 ± 1.1
Plasma norepinephrine ng/100mL 28 ± 3∗ 24 ± 22 5 ± 32 4 ± 2
Platelet calcium nMol/L 161 ± 18∗ 105 ± 12 135 ± 12∗ 112 ± 15
Norepinephrine pressor dose ng/kg/min 95 ± 13∗ Not done 115 ± 12∗ 132 ± 15
∗P<0.05 versus control subjects.
Group 1 hypercalcaemic, hypertensive patients with PHPT.
Group 2 hypercalcaemic, normotensive patients with PHPT.
Group 2 normocalcaemic, pre-hypertensive patients with PHPT.
Group 2 normal subjects.
all patients. Three months after surgery, blood pressure
recordings documented a reduction of high blood pressure
towards normotension in all patients (130/78 ± 6/4mmHg).
Norepinephrine pressor doses (135 ± 16ng/kg/min) were
higher and plasma renin activity (1.3 ± 0.3ng/mL/hr),
plasma aldosterone concentrations (4.1 ± 1.3ng/100mL),
and plasma norepinephrine levels (23 ± 3ng/100mL) were
signiﬁcantlylowerafterparathyroidectomyanddidnotdiﬀer
from values obtained from control subjects. Mean cytosolic
calcium levels in successfully treated hypercalcaemic PHPT
patients were signiﬁcantly lower than prior surgery (105
± 6nM/L) and comparable to values in normotensive
subjects.
4. Discussion
The main results of the present investigations demonstrate
that short-standing (known duration of high blood pressure
less than 6 months) parathyroid hypertension can be cured
by normalization of the hyperactive parathyroid metabolism
in patients who do not have primary hypertension.
The pathophysiology of hyperparathyroid hypertension
isstillanareaofresearch,butatleastthreetheorieshavebeen
proposed to explain increased total peripheral resistance [12,
13]. Firstly, major pressor factors causing vasoconstriction
such as the renin-angiotensin-aldosterone system and the
activity of the peripheral sympathetic nervous system were
found to be higher in hypertensive patients with PHPT
compared to controls. These abnormalities were reversed
by successful parathyroidectomy. However, the diﬀerences
in these pressor factors among hypertensive patients with
PHPTandage-,sex-andbodyweight-matchedcontrolswere
small.Nevertheless,thepressoreﬀectofanyvasoactivefactor
depends not only on its circulating concentration but also on
its cardiovascular reactivity.
Secondly, one major ﬁnding of our present study
is the demonstration of a signiﬁcantly enhanced pressor
response of the cardiovascular system to norepinephrine,
although circulating plasma norepinephrine levels were
slightly increased or normal in all patients with PHPT. These
data are in line with other observations [14, 15, 26]a n d
they suggest that parathyroid hypertension may be initiated
andmaintainedbyanexaggeratedcardiovascularresponseto
vasoactive hormones. The enhanced cardiovascular reactiv-
itytonorepinephrinecouldbetheconsequenceoffunctional
alterations or structural changes in the blood vessel walls.
The concentration of intracellular calcium in platelets
has been found to be elevated in primary and various forms
ofsecondaryhypertension[25,27–32].Weandotherinvesti-
gatorsmeasuredhighlyincreasedcytosolicfreecalciumlevels
in platelets in hypercalcaemic hypertensive patients with
PHPT, intermediately increased cytosolic free calcium levels
in prehypertensive patients with normocalcaemic PHPT
[33] and normal levels in normotensive hypercalcaemic
patients with PHPT [26, 34]. It has to be kept in mind,
however, that these ﬁndings in platelets cannot necessarily
be extrapolated to cytosolic levels in vascular muscle cells.
However, there was a strong correlation between platelet
cytosolic calcium concentrations and mean arterial pressure
when all groups of participants were considered jointly.
The elevated intracellular calcium concentrations found in
our patients with PHPT were not irreversible, since they
could be reverted to the normal range after successful
parathyroidectomy.
If the results obtained in platelets are indeed representa-
tive for vascular smooth muscle cells, functional alterations
characterized by an abnormal calcium metabolism at the
level of vascular smooth muscle cells may be the ﬁnal
common pathway for the enhanced vascular reactivity to
pressorhormonesandtheincreasedvasculartone andﬁnally
for increased peripheral vascular resistance.
Thirdly, structural changes in the vessels may maintain
high blood pressure in PHPT, but such changes may occur as
aresultofeitherlongstandinghypertension,hypercalcaemia,
or metabolic abnormalities associated with PHPT (dyslip-
idaemia, diabetes), or a combination of these. Structural
changes can lead to impaired vasoreactivity in patients with
PHPT which is not improved by successful parathyroidec-
tomy [18]. Rodriguez-Portales and Fardella [19]f o u n da
persistingabnormalpressorreactivitytonorepinephrinein7
normotensive patients with PHPT after parathyroidectomy,
and these authors postulated secondary structural changesInternational Journal of Endocrinology 5
in the vascular walls. To what extent structural changes
in the resistance vessel contribute to the maintenance of
hypertension in patients with PHPT is largely unknown.
The factors underlying the disturbances in cellular
calcium metabolism found in hypertension due to PHPT
are not well deﬁned. There are objections against the
hypothesis that hypercalcaemia per se or PTH causes
enhanced cellular inﬂux of calcium and raised cytosolic
calcium. In fact, hypercalcaemic PHPT may be associated
often with normotension, questioning the role of excess
calcium or increased PTH. Moreover, preincubation of
platelets of normotensive patients with exogenous iPTH
in vitro had no eﬀect on baseline cytosolic calcium [26,
28, 35]. Lewanczuk et al. [36] showed that the diseased
parathyroid glands in hypertensive patients with PHPT
express a low molecular weight circulating parathyroid
hypertensive factor (PHF) that was signiﬁcantly higher in
hypertensive patients with PHPT than in normotensive
patients with PHPT. Postoperatively, PHF was undetectable
in PHF-positive patients. Our previous in vitro studies with
platelets obtained from normotensive controls and plasma
derived from hypertensive patients with PHPT are well
comparable with in vitro studies by Barbagallo et al. [37]
who found that PHF increased free intracellular calcium in
erythrocytes. Unfortunately the molecular structure of this
putative factor is still not elucidated.
Left ventricular hypertrophy is a common ﬁnding in
patients with PHPT although this ﬁnding may be related
primarily to excess parathyroid hormone secretion and not
to hypertension. Previous studies have shown that successful
parathyroidectomy may lead to reversal of left ventricular
hypertrophy even in PHPT patients with normal resting
blood pressure [38].
5. Conclusion
Given the high prevalence of chronic arterial hypertension
(30% of the US population [39]) and the relatively low
prevalence of PHPT (0.1–0.7% [40, 41]), there is no doubt
that PHPT may often coexist with primary chronic arterial
hypertension. Both forms of hypertension are lacking a
measurable biochemical factor diﬀerentiating hypertensive
factorspathognomonic for one or the other. This coexistence
may however explain the discrepant results of parathyroidec-
tomy on high blood pressure in this patient group.
Undoubtedly, there is a need for further investigations to
clarify the pathogenesis of parathyroid hypertension.
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